Recurrent and founder mutations in the Netherlands-Phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy

Netherlands Heart Journal

Volumn 21, Issue 6, 2013, Pages 286-293

  van der Zwaag, P A ^a   van Rijsingen, I A W ^b   de Ruiter, R ^a,c   Nannenberg, E A ^b   Groeneweg, J A ^d,e   Post, J G ^d   Hauer, R N W ^d,e   van Gelder, I C ^a   van den Berg, M P ^a   van der Harst, P ^a,c   Wilde, A A M ^b   van Tintelen, J P ^a,c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Durrer Center for Cardiogenetic Research   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

ARVC D; Cardiomyopathy; DCM; Founder mutation; Genetics; PLN

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; FEMALE; GENE; GENE MUTATION; HAPLOTYPE; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; NETHERLANDS; PHOSPHOLAMBAN GENE; PREVALENCE; PROSPECTIVE STUDY; SEQUENCE ANALYSIS;

EID: 84878225366     PISSN: 15685888     EISSN: 18766250     Source Type: Journal    
DOI: 10.1007/s12471-013-0401-3     Document Type: Article

References (37)

1. Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. N Engl J Med. 2011;364:1643-56.
2. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807-16.
3. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270-6.
4. Thierfelder L, Watkins H, MacRae C, et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell. 1994;77:701-12.
5. Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003;107:2227-32.
6. Van Driest SL, Ommen SR, Tajik AJ, et al. Sarcomeric genotyping in hypertrophic cardiomyopathy. Mayo Clin Proc. 2005;80:463-9.
7. Christiaans I, Nannenberg EA, Dooijes D, et al. Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands. Neth Heart J. 2010;18:248-54.
8. Hershberger RE, Norton N, Morales A, et al. Coding sequence rare variants identified in MYBPC3, MYH6, TPM1, TNNC1, and TNNI3 from 312 patients with familial or idiopathic dilated cardiomyopathy. Circ Cardiovasc Genet. 2010;3:155-61.
9. Basso C, Corrado D, Marcus FI, et al. Arrhythmogenic right ventricular cardiomyopathy. Lancet. 2009;373:1289-300.
10. Sen-Chowdhry S, Syrris P, Ward D, et al. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation. 2007;115:1710-20.
11. Van Tintelen JP, Hofstra RM, Wiesfeld AC, et al. Molecular genetics of arrhythmogenic right ventricular cardiomyopathy: emerging horizon? Curr Opin Cardiol. 2007;22:185-92.
12. Sen-Chowdhry S, Syrris P, McKennaWJ. Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2007;50:1813-21.
13. Den Haan AD, Tan B, Zikusoka M, et al. Comprehensive desmosome mutation analysis in North Americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Cardiovasc Genet. 2009;2:428-35.
14. Cox MG, van der Zwaag PA, van der Werf C, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: pathogenic desmosome mutations in index-patients predict outcome of family screening: Dutch arrhythmogenic right ventricular dysplasia/cardiomyopathy genotypephenotype follow-up study. Circulation. 2011;123:2690-700.
15. Elliott P, O'Mahony C, Syrris P, et al. Prevalence of desmosomal protein gene mutations in patients with dilated cardiomyopathy. Circ Cardiovasc Genet. 2010;3:314-22.
16. Sen-Chowdhry S, Morgan RD, Chambers JC, et al. Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment. Annu Rev Med. 2010;61:233-53.
17. Dellefave L, McNally EM. The genetics of dilated cardiomyopathy. Curr Opin Cardiol. 2010;25:198-204.
18. MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol. 2003;4:566-77.
19. Schmitt JP, Kamisago M, Asahi M, et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science. 2003;299:1410-3.
20. Haghighi K, Kolokathis F, Pater L, et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest. 2003;111:869-76.
21. Haghighi K, Kolokathis F, Gramolini AO, et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc Natl Acad Sci USA. 2006;103:1388-93.
22. DeWitt MM, MacLeod HM, Soliven B, et al. Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1396-8.
23. Chiu C, Tebo M, Ingles J, et al. Genetic screening of calcium regulation genes in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2007;43:337-43.
24. Landstrom AP, Adekola BA, Bos JM, et al. PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases: summary of the literature and implications for genetic testing. Am Heart J. 2011;161:165-71.
25. Medeiros A, Biagi DG, Sobreira TJ, et al. Mutations in the human phospholamban gene in patients with heart failure. Am Heart J. 2011;162:1088-1095. e1.
26. Van der Zwaag PA, van Rijsingen IA, Asimaki A, et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail. 2012;14:1199-207.
27. Postema PG, Van den Berg M, Van Tintelen JP, et al. Founder mutations in the Netherlands: SCN5a 1795insD, the first described arrhythmia overlap syndrome and one of the largest and best characterised families worldwide. Neth Heart J. 2009;17:422-8.
28. Van der Zwaag PA, Cox MG, van der Werf C, et al. Recurrent and founder mutations in the Netherlands: plakophilin-2 pArg79X mutation causing arrhythmogenic right ventricular cardiomyopathy/ dysplasia. Neth Heart J. 2010;18:583-91.
29. Van den Wijngaard A, Volders P, Van Tintelen JP, et al. Recurrent and founder mutations in the Netherlands: cardiac Troponin I (TNNI3) gene mutations as a cause of severe forms of hypertrophic and restrictive cardiomyopathy. Neth Heart J. 2011;19:344-51.
30. Van Spaendonck-Zwarts KY, van der Kooi AJ, et al. Recurrent and founder mutations in the Netherlands: the cardiac phenotype of DES founder mutations p. S13F and p. N342D. Neth Heart J. 2012;20:219-28.
31. Machado PM, Brandao RD, Cavaco BM, et al. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol. 2007;25:2027-34.
32. Hillege HL, Janssen WM, Bak AA, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med. 2001;249:519-26.
33. Linssen GC, Bakker SJ, Voors AA, et al. N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J. 2010;31:120-7.
34. Posch MG, Perrot A, Geier C, et al. Genetic deletion of arginine 14 in phospholamban causes dilated cardiomyopathy with attenuated electrocardiographic R amplitudes. Hear Rhythm. 2009;6:480-6.
35. Gomez Milanes I, Garcia-Molina E, Sabater-Molina M, et al. R14Del, a Dutch phospholamban mutation in a Spanish family. Genotype-phenotype aspects. Eur Heart J. 2012;33 Suppl. 1:877. Abstract.
36. Zeegers MP, van Poppel F, Vlietinck R, et al. Founder mutations among the Dutch. Eur J Hum Genet. 2004;12:591-600.
37. Statline; Centraal Bureau voor de Statistiek. http://statline.cbs.nl (24/206/2012)